Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Blood Cancer Journal, Published online: 11 May 2020; doi:10.1038/s41408-020-0311-8Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

http://feeds.nature.com/~r/bcj/rss/current/~3/rqmJNfxMX-U/s41408-020-0311-8

Source: Blood Cancer Journal - May 10, 2020 Category: Hematology Authors: Brian G. M. Durie Antje Hoering Rachael Sexton Muneer H. Abidi Joshua Epstein S. Vincent Rajkumar Angela Dispenzieri Stephen P. Kahanic Mohan C. Thakuri Frederic J. Reu Christopher M. Reynolds Robert Z. Orlowski Bart Barlogie Source Type: research